About us
Meet our team over 125 years total experience
NICK DEMINICO
US/LATAM GMDP Quality Expert and Auditor
Specialising in
Manufacturing Operations
Process and CMC/MSAT
THOMAS DENTON
UK/EU/ROW GMDP, GCP Quality Expert, Auditor & Trainee QP
Specialising in
Strategy
Project management
Validation and Compliance
Risk Management
NARESH RENIKINDI
UK/EU QP/RP/RPi GMDP Expert
Specialising in
Clinical & Commercial, Borderline & Combination products
Manufacturing and Distribution of range of Small & Large molecules
Expert GMDP auditor & remediation consultant
Sterile products
LUCIA DALVIT
UK / EU QP Quality GMDP Expert
Specialising in
Quality Systems and Processes
Imports and Export, Compliance
IMPs
Continuous Improvement
Our Partners
Our Timeline
2023
-
June 2023 – Genesis of TDP
Founded in response to inefficiencies in pharmaceutical consulting, with a vision to deliver precise, flexible, and patient-centred solutions across the UK, US, and EU. -
August 2023 – UK Business Formation
Established UK entity, built IT infrastructure, and achieved Cyber Essentials certification. Plans underway for ISO 9001 & 27001.
2024
-
January 2024 – AAV Batch Certification
Provided over 300 hours of QP support for the urgent launch of a rare disease therapy, ensuring timely patient access.February 2024 – NHS Supplier QTA Review
Audited QTAs for GMP alignment and risk management across supplier agreements.February 2024 – MIA Set-up in Malta
Helped secure MIA/WDA through SOP gap analysis and regulatory adaptation.March 2024 – Strategic Supply Crisis Support
Guided a client through post-M&A supply shortages and regulatory complexity, helping them avoid contract fines and ensure product availability. -
April 2024 – ISO 17025 Audit and Gap Assessment
Supported a start-up aiming for ISO 17025 accreditation by performing a 7-day audit, gap analysis, and implementation of changes, leading to successful certification.April 11, 2024 – Establishing the US Presence
Formally registered the US entity in Delaware and integrated it into the existing operational infrastructure.April–June 2024 – Batch Review Contract
Supported gene therapy product certification for Duchenne Muscular Dystrophy clinical trials, ensuring continuous product supply across UK/EU by bridging US and EU regulatory frameworks.March–June 2025 – Integrated Eco-lane Collaboration
Partnered with GDP-UCI to develop logistics solutions for co-shipping across transport modes. Project was ultimately shelved due to cost and conflicting priorities. -
August 2024 – IMP MIA Application Support
Helped a client develop and implement a QMS to secure a Manufacturing and Import Authorisation through detailed inspections, gap analysis, and validation support.September 2024 – QMS Remediation
Remediated regulatory findings for a medical device/pharmaceutical product through QMS restructuring and strategic CAPA planning, resulting in regulatory approval.September 2024 – Urgent Due Diligence Audit
Executed a rapid, complex audit in just 15 days to support a critical NHS supply tender, enabling the client to qualify.September 2024 – Returning Client – Batch Reviews
Performed 7 complex Analytical & Accountability batch reviews involving 70GB+ of data, resolving major deviations and achieving timely QP certification. -
October 2024 – New Client Batch Reviews
Reviewed and certified 25 batches in just 4 weeks, helping the client meet sudden market demand and avoid shortages.October 2024 – EU and US GMP Audit (Florida)
Audited a biofermentation facility for EU and FDA compliance, providing clear insight and recommendations for global regulatory adherence.October 2024 – Mar 2025 – Interim Global Director of Audit
Led global audit strategy, trained US teams on EU GMP, redesigned audit plan, and strengthened supplier quality assurance.October & December 2024 – Complex Batch Recovery
Recovered two major batches from likely rejection by resolving critical deviations and achieving QP certification in April 2025.November 2024 – First US Client Audit (Canada)
Audited proprietary cell line management practices in Mississauga, identifying key documentation gaps for corrective action.December 2024 – Christmas Audits (China & India)
Conducted urgent anti-malarial audits over the holidays for an NGO, enabling the client to meet strict funding milestones.
2025
-
January 2025 – Return to China (NGO Audits)
Completed in-depth supply chain audits in China, ensuring the timely delivery of anti-malarial treatments and compliance with funding terms.January 2025 – USA Medical Device Importation Training
Delivered targeted training on US medical device and combination product import/export compliance for a blue-chip pharma client.February 2025 – Medicinal Cannabis Market Entry Review
Investigated the UK market potential for a cannabis product, providing a strategic report on licensing, QMS alignment, and barriers to entry. Client chose not to proceed.
Where are we?
We work remotely or from your site
We work efficiency and productively with no travel time
We work on your time zone and to your availability
Remote by design, for your needs
